| |
Year:
2013
| Volume: 21
| Issue: 1
| Pages: 17-19
|
| |
Review Article |
| |
CD30 – THE HEAD OF TNF-FAMILY…OR A SUCCESSFUL STORY OF BRENTUXIMAB VEDOTIN
Lazar Popovic, Darjana Jovanovic, ?orde Popovic |
| |
DOI:
10.2298/AOO1301017P |
| |
Abstract: |
| |
Hodgkin lymphoma and anaplastic large cell lymphoma are malignancies that highly express CD30 antigen on the cell surface. Both are generally curable by standard chemotherapy but refractory diseases and relapses are treatment problems. Brentuximab-vedotin is a labeled monoclonal antibody against CD30 and it is approved for the treatment of Hodgkin lymphoma relapsed after autologous stem cell transplantation and for relapsed anaplastic large cell lymphoma. This is the first drug approved for the treatment of Hodgkin lymphoma after 30 years. |
| |
Key words:
Hodgkin Disease; Antigens, CD30; Antineoplastic Agents; Antibodies, Monoclonal; Lymphoma, Large Cell, Anaplastic; Hematopoietic Stem Cell Transplantation |
| |
Read
full text in PDF [Full
Text] |
|
|